Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Hautarzt ; 70(2): 107-115, 2019 Feb.
Artigo em Alemão | MEDLINE | ID: mdl-30656382

RESUMO

Angioedema is a spontaneous, edematous swelling of the deep layers of the skin or mucous membrane. Angioedema in the respiratory tract is potentially life-threatening. The classification of angioedema into mast-cell-mediated (e. g. urticaria) or bradykinin-mediated (e. g. hereditary angioedema) is important for correct and rational treatment. Generally, two therapeutic strategies are available for angioedema treatment. On-demand treatment of angioedema symptoms that already have emerged aims to stop the further development of the attack and, thus, limits the severity and duration of the attack. This strategy is well established in the treatment of patients with hereditary angioedema, whereas in chronic spontaneous urticaria on-demand therapy plays no role in the guideline recommendations. In contrast, the therapeutic strategy of prophylaxis aims to prevent the occurrence of spontaneous and induced attacks as far as possible. Prophylaxis is the sole therapy strategy for chronic urticaria and is applied at all stages of the treatment algorithm. In the case of hereditary angioedema, on-demand therapy can be complemented by prophylaxis after careful and individual indication. In hereditary angioedema, prophylaxis is currently gaining in importance due to improved treatment options. Patients who use a prophylactic regime are much less likely to be forced to wait for the unpredictable occurrence of an attack and then to react with an on-demand treatment. Prophylactic treatment takes place at times determined by the patient himself, in contrast to treatment on an as-needed basis. The loss of unpredictability is a decisive moment in improving the quality of life.


Assuntos
Angioedema , Angioedemas Hereditários , Angioedema/prevenção & controle , Angioedemas Hereditários/prevenção & controle , Bradicinina , Proteína Inibidora do Complemento C1 , Humanos , Qualidade de Vida
2.
J Eur Acad Dermatol Venereol ; 27(9): 1063-70, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23302006

RESUMO

In the adult female, acne is a chronic condition with a substantial negative psychological, social and emotional impact. Based on time of onset, two subtypes of adult female acne are recognized: 'persistent acne' is a continuation of the disease from adolescence, while 'late-onset acne' first presents in adulthood. The morphological characteristics of adult female acne are often distinct from adolescent acne. In adults, inflammatory lesions (particularly papules, pustules and nodules) are generally more prominent on the lower chin, jawline and neck, and comedones are more often closed comedones (micro cysts). Adult acne is mainly mild-to-moderate in severity and may be refractory to treatment. A holistic approach to acne therapy should be taken in adult females, which combines standard treatments with adjunctive therapy and cosmetic use. A number of factors specific to the adult female influence choice of treatment, including the predisposition of older skin to irritation, a possible slow response to treatment, a high likelihood of good adherence, whether of child-bearing age, and the psychosocial impact of the disease. Adherence to therapy should be encouraged through further patient education and a simplified regimen that is tailored to suit the individual patient's needs and lifestyle. This article reviews the specific characteristics of adult female acne, and provides recommendations for acne therapy in this patient group.


Assuntos
Acne Vulgar , Acne Vulgar/tratamento farmacológico , Acne Vulgar/terapia , Adulto , Terapia Combinada , Feminino , Humanos
3.
Hautarzt ; 63(7): 567-72, 2012 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-22751857

RESUMO

The differentiation between mast cell mediator-mediated and bradykinin-mediated forms of angioedema can be difficult. Bradykinin-mediated hereditary angioedema is a rare autosomal dominant hereditary disease which is characterized by recurrent edema attacks of varying magnitude. The edema occurs in the skin and mucous membranes and can be temporarily disfiguring, very painful and life-threatening by attacks in the laryngeal region. Because of the multitude of differential diagnoses, a final diagnosis is only achieved after an average duration of more than 10 years. The anamnestic and laboratory diagnostic algorithm presented here is designed to assist a simpler differentiation of the various forms of angioedema and to reach the correct diagnosis more quickly.


Assuntos
Algoritmos , Angioedemas Hereditários/classificação , Angioedemas Hereditários/diagnóstico , Dermatologia/normas , Guias de Prática Clínica como Assunto , Diagnóstico Diferencial , Humanos
4.
J Clin Pharm Ther ; 35(6): 639-56, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21054455

RESUMO

WHAT IS KNOWN AND OBJECTIVES: Fibromyalgia (FBM) is a common chronic pain disorder affecting up to 2% of the general population. Current treatment options are mostly symptom-based and limited both in efficacy and number. Two promising alternatives are gabapentin (GP) and pregabalin (PB). We aimed to estimate the efficacy and safety/tolerability of the two compounds in FBM through a systematic review and a meta-analysis of relevant randomized double-blind placebo-controlled (RCT) were performed. DATA SOURCES, EXTRACTION AND ANALYSIS: A literature search was conducted through MEDLINE, EMBASE, Cochrane CENTRAL and the reference lists of relevant studies. Responders to treatment (>30% reduction in mean pain score) and dropouts due to lack of efficacy were used as primary outcome measures. Dropout rates and incidence of common adverse outcomes were also investigated. Four RCTs, reporting data on 2040 patients, were reviewed and three of them using PG were included in the meta-analysis. RESULTS: Pregabalin at a dose of 600, 450 and 300 mg per day is effective in FBM compared to placebo (NNT: 7, upper 95% CI: 12, 450 mg). A number of adverse events (AE), such as dizziness, somnolence, dry mouth, weight gain, peripheral oedema, is consistently associated with treatment at any dose and could lead one out of four patients to quit treatment (NNH: 6, lower 95% CI: 4, 600 mg). Indirect comparison meta-analysis suggests that PB at a dose of 450 mg per day could result in more responders than at 300 mg, but this result needs to be interpreted with caution as there were no significant differences between 600 and 300 mg or between 600 and 450 mg. Data on GP is limited. WHAT IS NEW AND CONCLUSIONS: The analysis indicates that PB at a dose of 450 mg per day is most likely effective in treating FBM, although AE are not negligible. Further evidence is necessary for more conclusive inferences.


Assuntos
Aminas/uso terapêutico , Analgésicos não Narcóticos/uso terapêutico , Ácidos Cicloexanocarboxílicos/uso terapêutico , Fibromialgia/tratamento farmacológico , Ácido gama-Aminobutírico/análogos & derivados , Aminas/efeitos adversos , Analgésicos não Narcóticos/efeitos adversos , Ácidos Cicloexanocarboxílicos/efeitos adversos , Relação Dose-Resposta a Droga , Feminino , Fibromialgia/fisiopatologia , Gabapentina , Humanos , Masculino , Avaliação de Resultados em Cuidados de Saúde , Dor/tratamento farmacológico , Pregabalina , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Ácido gama-Aminobutírico/efeitos adversos , Ácido gama-Aminobutírico/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA